Valuation: Cogent Biosciences, Inc.

Market Cap 5.23B 4.67B 4.36B 3.96B 7.46B 506B 7.52B 52.4B 20.47B 257B 19.64B 19.21B 827B P/E 2026 *
-13.4x
P/E 2027 * -28.7x
Enterprise Value 5.1B 4.56B 4.25B 3.86B 7.28B 494B 7.33B 51.11B 19.97B 251B 19.15B 18.74B 807B EV / Sales 2026 *
852x
EV / Sales 2027 * 17.2x
Free-Float
99.51%
Yield 2026 *
-
Yield 2027 * -
1 day-0.79%
1 week-5.87%
Current month-5.87%
1 month-13.29%
3 months-24.67%
6 months-15.38%
Current year-15.15%
1 week 29.7
Extreme 29.7
32.29
1 month 29.7
Extreme 29.7
35.57
Current year 29.7
Extreme 29.7
43.39
1 year 13.78
Extreme 13.78
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 2020-10-22
Director of Finance/CFO 45 2018-05-31
Chief Tech/Sci/R&D Officer 52 2021-04-05
Director TitleAgeSince
Director/Board Member 68 2018-01-31
Director/Board Member 74 2019-07-25
Director/Board Member 59 2019-07-25
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Free

Director

759 0.0004%
8/27/26 Exercice

Director

136,530 0.0787%
7/1/26 Free

Director

627 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-0.79%-5.87%+95.21%+199.01% 5.27B
+4.16%+4.16%+49.37%+94.17% 74.69B
+0.46%-0.97%+23.51%+79.34% 58.81B
+0.17%+0.35%+6.85%+34.55% 48.45B
+0.50%-2.14%+331.33%+702.20% 42.84B
-0.72%-3.99%+28.50%+29.94% 42.79B
+0.34%-0.52%+6.56%+109.35% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-0.88%+0.18%+33.69%+25.06% 30.28B
-0.50%-3.10%-10.19%-14.35% 24.05B
Average +0.25%-0.81%+57.40%+131.19% 39.96B
Weighted average by Cap. +0.75%-0.57%+56.68%+131.02%

Financials

2026 *2027 *
Net sales 5.99M 5.35M 4.99M 4.53M 8.54M 579M 8.6M 59.99M 23.44M 295M 22.48M 22M 947M 293M 262M 244M 222M 418M 28.33B 421M 2.93B 1.15B 14.41B 1.1B 1.08B 46.31B
Net income -399M -356M -333M -302M -569M -38.59B -573M -4B -1.56B -19.63B -1.5B -1.47B -63.09B -202M -181M -169M -153M -289M -19.57B -291M -2.03B -792M -9.95B -760M -743M -32B
Net Debt -130M -116M -108M -98.17M -185M -12.54B -186M -1.3B -507M -6.38B -487M -476M -20.5B -206M -184M -172M -156M -294M -19.94B -296M -2.06B -807M -10.14B -774M -757M -32.59B
Projected Income Statement - Annual - Cogent Biosciences, Inc.
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
26-10-07 US$30.14 -0.79% 1,262,893
26-10-06 US$30.38 -1.59% 2,383,802
26-10-05 US$30.87 -0.48% 1,792,883
26-10-02 US$31.02 -1.80% 1,172,134
26-10-01 US$31.59 -1.34% 1,698,630
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Ratings Surperformance© - Cogent Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
30.14USD
Average target price
55.82USD
Spread / Average Target
+85.20%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cogent Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. COGT Stock